GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...
10月29日，葛兰素史克发布公告：与中国企业恩沐生物达成协议，以3亿美元的预付款收购 ... 根据公告，GSK计划重点关注CMG1A46在治疗系统性红斑狼疮 ...
Nov. 1, 2024 — Biomedical engineers have invented a 3D printing system, or bioprinter, capable of fabricating structures that closely mimic the diverse tissues in the human body, from soft brain ...
Combining the science of the immune system and human genetics with advanced technologies is the cornerstone of R&D at GSK ... adults—into phase 2 or 3 trials. GSK is committed to accelerating ...
Oct 8 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients ...
GSK GSK0.31%increase; green up pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...
GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...
GSK PLC GSK shares advanced 3.22% to £15.05 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 0.07% to 8,237.73.
"The settlement of $2.2 billion is lower than market expectations of $3.5 billion, and the announcement came sooner than expected. The Zantac clouds are lifting, and GSK will likely resolve the ...
GSK (GSK) came out with quarterly earnings of ... Glaxo shares have added about 3% since the beginning of the year versus the S&P 500's gain of 22.3%. While Glaxo has underperformed the market ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈